T-group (topology)
109.3.1 Ankyrin repeat
Ligands and drugs
9,610
Member domains
1,534
with ligand contacts (≤ 4 Å)
16.0% of members
341
with DrugDomain annotations
3.5% of members
147
with a DrugBank compound
1.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 109.3.1 belongs to X-group 109 Repetitive alpha hairpins, which binds 9.1 ligand superclasses per 20 proteins, broader than 82% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03775 | DTB | Dethiobiotin | 12 |
| DB09061 | — | Cannabidiol | 6 |
| DB12010 | — | Fostamatinib | 6 |
| DB14011 | — | — | 6 |
| DB00825 | — | — | 4 |
| DB01744 | — | Camphor | 4 |
| DB03401 | I3P | 1D-myo-inositol 1,4,5-trisphosphate | 4 |
| DB11148 | — | — | 4 |
| DB11345 | — | — | 4 |
| DB11755 | — | Tetrahydrocannabivarin | 4 |
| DB14050 | — | — | 4 |
| DB00171 | ATP | ATP | 3 |
| DB03904 | URE | Urea | 3 |
| DB00142 | — | Glutamic acid | 2 |
| DB00795 | — | Sulfasalazine | 2 |
| DB01103 | — | — | 2 |
| DB03103 | TYD | Thymidine-5'- Diphosphate | 2 |
| DB03309 | NHE | N-cyclohexyltaurine | 2 |
| DB03725 | GCP | 5'-Guanylylmethylenebisphosphonate | 2 |
| DB05212 | — | — | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| Y01 | CHOLESTEROL HEMISUCCINATE | 270 |
| CAmetal | CALCIUM ION | 214 |
| ZNmetal | ZINC ION | 145 |
| PIO | [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate | 94 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 76 |
| MGmetal | MAGNESIUM ION | 69 |
| CLR | CHOLESTEROL | 68 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 36 |
| XJ7 | (2S)-1-(butanoyloxy)-3-{[(R)-hydroxy{[(1r,2R,3S,4S,5R,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propan-2-yl tridecanoate | 34 |
| A1AIB | (2S)-2-(3,4-dihydroquinolin-1(2H)-yl)-N-(5-methyl-1,2-oxazol-3-yl)-2-phenylacetamide | 28 |
| CL | CHLORIDE ION | 28 |
| A1CGW | 5-chloro-N-[(5-chloro-1,3-thiazol-2-yl)methyl]-1,2-benzothiazol-6-amine | 24 |
| 8IJ | (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctadecanoate | 23 |
| A1AIA | primidone | 21 |
| FZ4 | 2-aminoethyl diphenylborinate | 20 |
| 6OU | [(2~{R})-1-[2-azanylethoxy(oxidanyl)phosphoryl]oxy-3-hexadecanoyloxy-propan-2-yl] (~{Z})-octadec-9-enoate | 19 |
| NAmetal | SODIUM ION | 17 |
| 9PE | (1R)-2-{[(S)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-1-[(heptanoyloxy)methyl]ethyl octadecanoate | 16 |
| A1CG0 | (2R)-2-(hydroxymethyl)-4-{[(10xi,13xi,22xi,25R)-5beta,14beta,17beta-spirostan-3beta-yl]oxy}butyl 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranoside | 16 |
| A1CGZ | Tigogenin | 16 |